Federal health officials say an implant from Indiana-based Zimmer Holdings Inc. appears to be effective in treating spinal
problems, but questions remain about whether company payments to doctors influenced the device’s trial data.
Biotechnology behemoth Amgen Inc. is being sued by 15 states, including Indiana, alleging the company gave kickbacks to medical
providers to help boost sales of the Aranesp.
Lilly is opening the San Diego biotech center a year after launching a biotech R&D center in Indianapolis.
After no Indiana health and life sciences firms announced venture capital deals in the second quarter, five did so in the
third, and two more have already this month.
Long tracking the emergence of information technology firms involved in the health and life sciences sector, the state’s
IT trade group, TechPoint, is undergoing a mitosis of sorts to help fuel the trend. It has created Advancing
Life Science & Health Care Information Technology, or ALHIT, which will focus on growing this subset of the IT realm.
Money will help the company refine its tool to treat acute kidney injury.
Dow AgroSciences, the local subsidiary of Midland, Mich.-based Dow Chemical Co., said Thursday that revenue fell 20 percent
and profits plummeted in the third quarter due largely to lower crop commodity prices.
The Warsaw-based company recorded a third-quarter profit of $150 million, down 30 percent from the same quarter a year ago.
Bloomington-based Cook Group Inc. could find itself cutting as many as 1,000 local jobs if Congress enacts a tax on
medical devices to pay for health care reform, company founder Bill Cook said in an interview.
Some of Indiana’s leading organizations in health information technology are collaborating on an effort to receive several
million dollars of stimulus funding.
The U.S. Department of Agriculture has given Purdue University a nearly $1 million grant to study ways that genomics can be
used to enhance the value of certain plants while making them more resilient to climate stress.
Dow AgroSciences’ introduction of a promising new product is helping transform the Indianapolis company as it transitions
from a focus on traditional agricultural chemicals to genetically altered seeds. The subsidiary of Michigan-based Dow Chemical
Co. partnered with St. Louis-based Monsanto Co. to develop what could become its biggest blockbuster, a genetically modified
corn variety it calls SmartStax.
BioCrossroads, an Indianapolis-based not-for-profit, is cataloging Indiana businesses offering contract services to pharmaceutical
and biotechnology companies, and discovering many small firms operating in relative obscurity.
Dow AgroSciences could boost its market share in genetically altered corn almost overnight by inventing a perennial corn.
But investors might not have the patience.
Officials of Purdue University and Dow AgroSciences unveiled a collaboration Wednesday in which the Indianapolis-based company
will become one of the largest tenants at the Purdue Research Park in West Lafayette.
A decision by a federal judge in Indianapolis to turn back a patent challenge to Eli Lilly and Co.’s Evista marks a major
victory for the company, says an analyst who closely follows the pharmaceutical industry.
A federal judge in Indianapolis turned back a patent challenge to Eli Lilly and Co.’s drug Evista, the company announced
late yesterday.
A new group expected to develop the orthopedic implants industry in Warsaw will be able to proceed now that Indianapolis-based
Lilly Endowment Inc. is putting $7 million behind it, according to an announcement this morning.
Biotechnology company Adolor Corp. said yesterday that it bought exclusive worldwide rights to Eli Lilly and Co.’s OpRA
III drug candidate, which has a range of potential uses.
Indianapolis-based Eli Lilly and Co. announced today that a clinical trial showed lung cancer patients treated with Lilly
drug Alimta lived about three months longer than those who received the best available care.
